Vilobelimab

Definition

A monoclonal antibody targeting the human complement factor C5a, with potential anti-inflammatory and immunomodulating activities. Upon administration, vilobelimab specifically targets and binds to C5a. This prevents the binding of C5a to its receptor C5a receptor (C5aR) and prevents C5a/C5aR-mediated pro-inflammatory signaling, thereby reducing inflammation and tissue and organ damage. C5a, a factor in the complement cascade, plays important roles in inflammation and immunity. C5aR is expressed on multiple cell types including mast cells, phagocytes, bronchial and alveolar epithelial cells, hepatocytes, astrocytes and vascular endothelial cells.

Also known as IFX 1, IFX-1, IFX1, VILOBELIMAB — per NCIT

Also identified as

• ATC L04AJ10 per RXNORM
• NCIT NCIT:C172643 per NCIT
• UNII F5T0RF9ZJA per RXNORM

Indications